RGNX supply chain intelligence for REGENXBIO Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| GLAXOSMITHKLINE-LLC | GLAXOSMITHKLINE-LLC | 90% | the Company will make a payment of $10.0 million to GSK within three business days of the Settlement Agreement effective date for alleged underpayment of sublicense fees on amounts received by the Co… |
| NOVARTIS-GENE-THERAPIES-INC | NOVARTIS-GENE-THERAPIES-INC | 90% | Under the Novartis License, the Company granted Novartis Gene Therapies an exclusive, worldwide commercial license, with rights to sublicense, to the NAV Technology Platform, as well as other certain… |
| DNLI | Denali Therapeutics Inc. | 72% | atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that will expire in 2040, one issued U.S. pate… |
| DNLI | Denali Therapeutics Inc. | 72% | Reciprocal relationship from DNLI graph: Reciprocal relationship from RGNX graph: Reciprocal relationship from DNLI graph: Reciprocal relationship from RGNX graph: atent that will expire in 2034, one… |
| FDMT | 4D Molecular Therapeutics, Inc. | 72% | Reciprocal relationship from FDMT graph: Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will exp… |
| FDMT | 4D Molecular Therapeutics, Inc. | 72% | atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that will expire in 2040, one issued U.S. pate… |
| OTLK | Outlook Therapeutics, Inc. | 72% | atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that will expire in 2040, one issued U.S. pate… |
| OTLK | Outlook Therapeutics, Inc. | 72% | Reciprocal relationship from OTLK graph: Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will exp… |
| RARE | Ultragenyx Pharmaceutical Inc. | 72% | Reciprocal relationship from RARE graph: Reciprocal relationship from RGNX graph: Reciprocal relationship from RARE graph: Reciprocal relationship from RGNX graph: Reciprocal relationship from RARE g… |
| RARE | Ultragenyx Pharmaceutical Inc. | 72% | atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that will expire in 2040, one issued U.S. pate… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will exp… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that will expire in 2040, one issued U.S. pate… |
| SRPT | Sarepta Therapeutics, Inc. | 72% | Reciprocal relationship from SRPT graph: Reciprocal relationship from RGNX graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from RGNX graph: atent that will expire in 2034, one… |
| SRPT | Sarepta Therapeutics, Inc. | 72% | atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that will expire in 2040, one issued U.S. pate… |
| TNYA | Tenaya Therapeutics, Inc. | 72% | atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that will expire in 2040, one issued U.S. pate… |
| TNYA | Tenaya Therapeutics, Inc. | 72% | Reciprocal relationship from TNYA graph: Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will exp… |
| TSHA | Taysha Gene Therapies, Inc. | 72% | Reciprocal relationship from TSHA graph: Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will exp… |
| TSHA | Taysha Gene Therapies, Inc. | 72% | atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that will expire in 2040, one issued U.S. pate… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| NIPPON-SHINYAKU | NIPPON-SHINYAKU | 92% | The Company concluded that each of the distinct units of account identified under the Nippon Shinyaku Collaboration Agreement should be accounted for as revenue under ASC 606, as Nippon Shinyaku is d… |
| NOVARTIS-GENE-THERAPIES | NOVARTIS-GENE-THERAPIES | 92% | Two customers (Novartis Gene Therapies and Nippon Shinyaku) accounted for approximately 99% of our total revenues for the year ended December 31, 2025. |
| NOVARTIS-GENE-THERAPIES-INC | NOVARTIS-GENE-THERAPIES-INC | 85% | the licensee. Royalty revenue to date consists primarily of royalties on net sales of Zolgensma and Itvisma, which are licensed products under the Company’s license agreement with Novartis Gene Thera… |
| NVSEF | Novartis AG | 85% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from RGNX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from RGNX graph: . (Novartis Gene Therapies), a wh… |
| NVSEF | Novartis AG | 85% | . (Novartis Gene Therapies), a wholly owned subsidiary of Novartis AG (Novartis), for the development and commercialization of treatments for spinal muscular atrophy (SMA). The Company recognizes roy… |
| DNLI | Denali Therapeutics Inc. | 72% | Reciprocal relationship from DNLI graph: Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will exp… |
| DNLI | Denali Therapeutics Inc. | 72% | atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that will expire in 2040, one issued U.S. pate… |
| FDMT | 4D Molecular Therapeutics, Inc. | 72% | Reciprocal relationship from FDMT graph: Reciprocal relationship from RGNX graph: Reciprocal relationship from FDMT graph: Reciprocal relationship from RGNX graph: Reciprocal relationship from FDMT g… |
| FDMT | 4D Molecular Therapeutics, Inc. | 72% | atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that will expire in 2040, one issued U.S. pate… |
| OTLK | Outlook Therapeutics, Inc. | 72% | Reciprocal relationship from OTLK graph: Reciprocal relationship from RGNX graph: Reciprocal relationship from OTLK graph: Reciprocal relationship from RGNX graph: Reciprocal relationship from OTLK g… |
| OTLK | Outlook Therapeutics, Inc. | 72% | atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that will expire in 2040, one issued U.S. pate… |
| RARE | Ultragenyx Pharmaceutical Inc. | 72% | Reciprocal relationship from RARE graph: Reciprocal relationship from RGNX graph: Reciprocal relationship from RARE graph: Reciprocal relationship from RGNX graph: Reciprocal relationship from RARE g… |
| RARE | Ultragenyx Pharmaceutical Inc. | 72% | atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that will expire in 2040, one issued U.S. pate… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that will expire in 2040, one issued U.S. pate… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from RGNX graph: Reciprocal relationship from REGN graph: Reciprocal relationship from RGNX graph: atent that will expire in 2034, one… |
| SRPT | Sarepta Therapeutics, Inc. | 72% | atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that will expire in 2040, one issued U.S. pate… |
| SRPT | Sarepta Therapeutics, Inc. | 72% | Reciprocal relationship from SRPT graph: Reciprocal relationship from RGNX graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from RGNX graph: Reciprocal relationship from SRPT g… |
| TNYA | Tenaya Therapeutics, Inc. | 72% | atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that will expire in 2040, one issued U.S. pate… |
| TNYA | Tenaya Therapeutics, Inc. | 72% | Reciprocal relationship from TNYA graph: Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will exp… |
| TSHA | Taysha Gene Therapies, Inc. | 72% | atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that will expire in 2040, one issued U.S. pate… |
| TSHA | Taysha Gene Therapies, Inc. | 72% | Reciprocal relationship from TSHA graph: Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will exp… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| RGNX-DEBT | Debt stack $248.4M | 90% | Market cache reports total debt of $248.4M. |
| RGNX-DEBT-12160 | Warrants outstanding: 1610000 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| RGNX-DEBT-12161 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2015-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| RGNX-OWNER-MORGAN-STANLEY | MORGAN STANLEY | 90% | 13F overlay lists MORGAN STANLEY as top holder; 180 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ABT | Abbott Laboratories | 100.00 | 2 | |
| OTLK | Outlook Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CPMV | Mosaic ImmunoEngineering, Inc. | 100.00 | 2 | |
| ELVN | Enliven Therapeutics, Inc. | 100.00 | 2 | |
| ACET | Adicet Bio, Inc. | 100.00 | 2 | |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 100.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 100.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 | |
| ARTV | Artiva Biotherapeutics, Inc. | 100.00 | 2 | |
| CLPT | ClearPoint Neuro, Inc. | 100.00 | 2 | |
| SLGL | Sol-Gel Technologies Ltd. | 100.00 | 2 | |
| SDGR | Schrödinger, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| COLL | Collegium Pharmaceutical, Inc. | 100.00 | 2 |